COVID-19 has changed nearly every aspect of healthcare as we know it. Pharmaceutical commercial organizations must quickly adapt to the present while simultaneously planning for a dramatically different future.
The COVID-19 global pandemic, overcrowding of hospitals, the highly contagious virus affecting healthcare professionals and unrelated illnesses has led to a more than 1,000 percent increase of telemed application downloads and memberships. Is this a paradigm shift?
According to a study released by Infogroup, a provider of data and data-driven intelligence solutions, four in five consumers say they are more concerned about privacy than they used to be – a tendency marketers ought to keep in mind.
French healthcare company Sanofi and U.S. start-up technology company Luminostics said they were joining up to work on developing a smartphone-based self-testing solution to see if someone has the COVID-19 coronavirus.
In a competitive market, brands rely on their reputations to give them an edge. However, these reputations are built on perceptions — and because it’s up to consumers to develop their own perceptions, brands may feel as though they have less control in developing lasting loyalty. This is especially true in the pharmaceutical industry due to where pharmaceutical manufacturers reside within healthcare’s value chain. In the patient-doctor relationship, pharmaceutical companies are the left-out third wheel.
An advertising campaign called “Spread Facts, Not Fear” encourages safe habits and point people to the experts regarding the Covid-19 pandemic.
In these days of the COVID-19 epidemic, many in the pharma industry are facing the challenge of accessing their customers and engaging in communication. The good news is that there are virtual solutions and approaches that are proven to deliver when in-person selling is limited or no longer an option.
Have you ever tried to seesaw alone? Imagine the scene: a playground with two seesaws. On one sits a doctor. On the other one, a patient. The seesaw itself is your brand’s messaging – one seesaw has just HCP messaging and the other only DTC messaging. The doctor and the patient are both interacting with their seesaws – sitting motionless, perhaps even trying to make the seesaw move. But the magic really happens when you introduce one seesaw that integrates the messaging, placing both HCP and consumer together. The seesaw can finally move, and they’re together, interacting, integrating.
Industry contributors shared with Med Ad News topics that will have a major impact on pharma marketing during 2020.
A look at how the California Consumer Privacy Act put into effect in 2020 will impact the pharmaceutical industry.